CTX-471 is a fully human monoclonal antibody that binds and activates a novel epitope of the co-stimulatory receptor CD137, also known as 4-1BB, a member of the tumor necrosis factor receptor superfamily.
Preclinical data presented at the 2018 Society for Immunotherapy of Cancer Annual Meeting suggest that CTX has the potential to become a best-in-class CD137 agonist displaying curative monotherapy efficacy against multiple syngeneic tumor models and generation of long-term functional immunological memory. Most notably, CTX-471 is able to induce the complete eradication of large, established tumors where other preclinical CD137 antibodies and antibodies against PD-1, PDL, CTLA, and OX40 have minimal effect. CTX-471 profoundly reprograms the tumor microenvironment, increasing CD8+ T cell infiltration and penetration while reducing T-cell exhaustion. In contrast to other clinical and preclinical CD137 antibodies, CTX-471 shows no evidence of hepatic inflammation and toxicity in both mice and non-human primates, supporting a wide therapeutic window.
We are now enrolling patients in a Phase 1 clinical trial of CTX-471. Visit clinicaltrials.gov for more information.